tirzepatide and perimenopause GLP-1 Agonists in Perimenopause: Unique Risks Potential Opportunities The GLP-1/GIP dual-receptor agonist tirzepatide

From transformation to chronification of migraine: pathophysiological and clinical aspects

Each has a distinct mechanism, efficacy profile, supply situation, and indication, and your doctor matches the medication to your clinical picture rather than the reverse

Evaluation of malondialdehyde level, total oxidant/antioxidant status and oxidative stress index in colorectal cancer patients

When switching the GLP-1 component to tirzepatide, your provider may adjust or temporarily discontinue the phentermine during titration to isolate the effects of the new medication and manage side effects individually

Our providers will guide the best stack for your needs